News 23 Mar 2023 New Study Confirms Daxor’s BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients admin
News 23 Mar 2023 Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients admin
News 03 Mar 2023 Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders admin
News 02 Mar 2023 Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022 admin
News 01 Mar 2023 Daxor Corporation to Report Fiscal Year 2022 Financial Results on Wednesday, March 1, 2023 and Provide Corporate Update admin
